Show simple item record

dc.contributor.authorDitkowsky, Jared
dc.contributor.authorShah, Khushal H
dc.contributor.authorHammerschlag, Margaret R
dc.contributor.authorKohlhoff, Stephan
dc.contributor.authorSmith-Norowitz, Tamar A
dc.date.accessioned2023-07-07T16:44:45Z
dc.date.available2023-07-07T16:44:45Z
dc.date.issued2017-02-18
dc.identifier.citationDitkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infect Dis. 2017 Feb 18;17(1):155. doi: 10.1186/s12879-017-2248-5. PMID: 28214469; PMCID: PMC5316151.en_US
dc.identifier.eissn1471-2334
dc.identifier.doi10.1186/s12879-017-2248-5
dc.identifier.pmid28214469
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10401
dc.description.abstractChlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United States (U.S.) [1] and remains a major public health problem. We determined the cost- benefit of screening all pregnant women aged 15-24 for Chlamydia trachomatis infection compared with no screening.
dc.description.abstractWe developed a decision analysis model to estimate costs and health-related effects of screening pregnant women for C. trachomatis in a high burden setting (Brooklyn, NY). Outcome data was from literature for pregnant women in the 2015 US population. A virtual cohort of 6,444,686 pregnant women, followed for 1 year was utilized. Using outcomes data from the literature, we predicted the number of C. trachomatis cases, associated morbidity, and related costs. Two comparison arms were developed: pregnant women who received chlamydia screening, and those who did not. Costs and morbidity of a pregnant woman-infant pair with C. trachomatis were calculated and compared.
dc.description.abstractCost and benefit of screening relied on the prevalence of C. trachomatis; when rates are above 16.9%, screening was proven to offer net cost savings. At a pre-screening era prevalence of 8%, a screening program has an increased expense of $124.65 million ($19.34/individual), with 328 thousand more cases of chlamydia treated, and significant reduction in morbidity. At a current estimate of prevalence, 6.7%, net expenditure for screening is $249.08 million ($38.65/individual), with 204.63 thousand cases of treated chlamydia and reduced morbidity.
dc.description.abstractConsidering a high prevalence region, prenatal screening for C. trachomatis resulted in increased expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis.
dc.language.isoenen_US
dc.relation.urlhttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2248-5en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectC. trachomatisen_US
dc.subjectChlamydia screeningen_US
dc.subjectPregnant womenen_US
dc.titleCost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleBMC infectious diseasesen_US
dc.source.volume17
dc.source.issue1
dc.source.beginpage155
dc.source.endpage
dc.source.countryEngland
dc.description.versionVoRen_US
refterms.dateFOA2023-07-07T16:44:45Z
html.description.abstractChlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United States (U.S.) [1] and remains a major public health problem. We determined the cost- benefit of screening all pregnant women aged 15-24 for Chlamydia trachomatis infection compared with no screening.
html.description.abstractWe developed a decision analysis model to estimate costs and health-related effects of screening pregnant women for C. trachomatis in a high burden setting (Brooklyn, NY). Outcome data was from literature for pregnant women in the 2015 US population. A virtual cohort of 6,444,686 pregnant women, followed for 1 year was utilized. Using outcomes data from the literature, we predicted the number of C. trachomatis cases, associated morbidity, and related costs. Two comparison arms were developed: pregnant women who received chlamydia screening, and those who did not. Costs and morbidity of a pregnant woman-infant pair with C. trachomatis were calculated and compared.
html.description.abstractCost and benefit of screening relied on the prevalence of C. trachomatis; when rates are above 16.9%, screening was proven to offer net cost savings. At a pre-screening era prevalence of 8%, a screening program has an increased expense of $124.65 million ($19.34/individual), with 328 thousand more cases of chlamydia treated, and significant reduction in morbidity. At a current estimate of prevalence, 6.7%, net expenditure for screening is $249.08 million ($38.65/individual), with 204.63 thousand cases of treated chlamydia and reduced morbidity.
html.description.abstractConsidering a high prevalence region, prenatal screening for C. trachomatis resulted in increased expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalBMC infectious diseases
dc.identifier.issue1en_US


Files in this item

Thumbnail
Name:
s12879-017-2248-5.pdf
Size:
659.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International